Tazemetostat

GPTKB entity

Statements (40)
Predicate Object
gptkbp:instanceOf gptkb:drug
small molecule
gptkbp:approvalYear 2020
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
gptkbp:ATCCode L01XX71
gptkbp:brand gptkb:Tazverik
gptkbp:CASNumber 1403254-99-8
gptkbp:chemicalFormula https://pubchem.ncbi.nlm.nih.gov/compound/89683895
gptkbp:developer gptkb:Epizyme,_Inc.
gptkbp:hasMolecularFormula C34H44N4O4
gptkbp:hasSMILES CC1=CC(=O)N(C2=CC=CC=C12)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)N7CCN(CC7)C
https://www.w3.org/2000/01/rdf-schema#label Tazemetostat
gptkbp:KEGGID D11041
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction EZH2 inhibitor
gptkbp:molecularWeight 572.74 g/mol
gptkbp:pregnancyCategory not recommended
gptkbp:PubChem_CID gptkb:DB12983
gptkb:CHEMBL3137347
89683895
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:anemia
nausea
vomiting
constipation
fatigue
thrombocytopenia
decreased appetite
gptkbp:synonym gptkb:EPZ-6438
TAZVERIK
gptkbp:target gptkb:EZH2
gptkb:EZH1
gptkbp:UNII 6J8OL8451O
gptkbp:usedFor epithelioid sarcoma
follicular lymphoma
gptkbp:bfsParent gptkb:EPZ-6438
gptkb:EZH2_(human)
gptkb:KMT6
gptkbp:bfsLayer 8